HER-2/neu (657-665) represents an immunogenic epitope of HER-2/neu oncoprotein with potent antitumor properties

Vaccine

Volumn 28, Issue 1, 2009, Pages 162-170

  Gritzapis, Angelos D ^a   Fridman, Arthur ^b   Perez, Sonia A ^a   La Monica, Nicola ^c   Papamichail, Michael ^a   Aurisicchio, Luigi ^c   Baxevanis, Constantin N ^a  

^a SAINT SAVVAS HOSPITAL   (Greece)

^b MERCK RESEARCH LABORATORIES   (United States)

^c IRBM Oncology Department   (Italy)

Author keywords

Epitope; HLA A2.1; Tumor immunity; Vaccination

Indexed keywords

ALANYLVALYLVALYLGLYCYLISOLEUCYLLEUCYLLEUCYLVALYLVALINE; CANCER VACCINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPITOPE; GAMMA INTERFERON; HLA A2 ANTIGEN; HLA A2.1 ANTIGEN; PEPTIDE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN BINDING; ANTIGEN SPECIFICITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER GRAFT; CANCER IMMUNIZATION; CANCER INHIBITION; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DEGRANULATION; DRUG CYTOTOXICITY; IMMUNE RESPONSE; IMMUNOGENICITY; IN VITRO STUDY; IN VIVO STUDY; INTERFERON PRODUCTION; LYMPHOMA; LYMPHOMA CELL; MEMORY CELL; MOUSE; NONHUMAN; OVARY CANCER; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; TRANSGENIC MOUSE; TUMOR GROWTH; TUMOR IMMUNITY;

ANIMALS; ANTIGENS, NEOPLASM; CANCER VACCINES; CELL LINE, TUMOR; DENDRITIC CELLS; EPITOPES; FEMALE; HLA-A2 ANTIGEN; HUMANS; IMMUNOLOGIC MEMORY; INTERFERON-GAMMA; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, TRANSGENIC; PEPTIDE FRAGMENTS; RECEPTOR, ERBB-2; T-LYMPHOCYTES, CYTOTOXIC;

EID: 70649100026     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2009.09.104     Document Type: Article

References (38)

1. Baxevanis C.N., Sotiriadou N.N., Gritzapis A.D., Sotiropoulou P.A., Perez S.A., Cacoullos N.T., et al. Immunogenic HER-2/neu peptides as tumor vaccines. Cancer Immunol Immunother 55 1 (2006) 85-95
2. Kiessling R., Wei W.Z., Herrmann F., Lindencrona J.A., Choudhury A., Kono K., et al. Cellular immunity to the Her-2/neu protooncogene. Adv Cancer Res 85 (2002) 101-144
3. Gray A., Raff A.B., Chiriva-Internati M., Chen S.Y., and Kast W.M. A paradigm shift in therapeutic vaccination of cancer patients: the need to apply therapeutic vaccination strategies in the preventive setting. Immunol Rev 222 (2008) 316-327
4. Munn D.H., and Mellor A.L. Indoleamine 2,3-dioxygenase and tumor-induced tolerance. J Clin Invest 117 5 (2007) 1147-1154
5. Rabinovich G.A., Gabrilovich D., and Sotomayor E.M. Immunosuppressive strategies that are mediated by tumor cells. Annu Rev Immunol 25 (2007) 267-296
6. Baxevanis C.N., Perez S.A., and Papamichail M. Combinatorial treatments including vaccines, chemotherapy and monoclonal antibodies for cancer therapy. Cancer Immunol Immunother 58 3 (2009) 317-324
7. Begley J., and Ribas A. Targeted therapies to improve tumor immunotherapy. Clin Cancer Res 14 14 (2008) 4385-4391
8. Melief C.J., and van der Burg S.H. Immunotherapy of established (pre)malignant disease by synthetic long peptide vaccines. Nat Rev Cancer 8 5 (2008) 351-360
9. Holmes J.P., Benavides L.C., Gates J.D., Carmichael M.G., Hueman M.T., Mittendorf E.A., et al. Results of the first phase I clinical trial of the novel II-key hybrid preventive HER-2/neu peptide (AE37) vaccine. J Clin Oncol 26 20 (2008) 3426-3433
10. Holmes J.P., Gates J.D., Benavides L.C., Hueman M.T., Carmichael M.G., Patil R., et al. Optimal dose and schedule of an HER-2/neu (E75) peptide vaccine to prevent breast cancer recurrence: from US Military Cancer Institute Clinical Trials Group Study I-01 and I-02. Cancer 113 7 (2008) 1666-1675
11. Pascolo S., Bervas N., Ure J.M., Smith A.G., Lemonnier F.A., and Perarnau B. HLA-A2.1-restricted education and cytolytic activity of CD8(+) T lymphocytes from beta2 microglobulin (beta2m) HLA-A2.1 monochain transgenic H-2Db beta2m double knockout mice. J Exp Med 185 12 (1997) 2043-2051
12. Gritzapis A.D., Mahaira L.G., Perez S.A., Cacoullos N.T., Papamichail M., and Baxevanis C.N. Vaccination with human HER-2/neu (435-443) CTL peptide induces effective antitumor immunity against HER-2/neu-expressing tumor cells in vivo. Cancer Res 66 10 (2006) 5452-5460
13. Gritzapis A.D., Voutsas I.F., Lekka E., Tsavaris N., Missitzis I., Sotiropoulou P., et al. Identification of a novel immunogenic HLA-A*0201-binding epitope of HER-2/neu with potent antitumor properties. J Immunol 181 1 (2008) 146-154
14. Voutsas I.F., Gritzapis A.D., Mahaira L.G., Salagianni M., von Hofe E., Kallinteris N.L., et al. Induction of potent CD4+ T cell-mediated antitumor responses by a helper HER-2/neu peptide linked to the Ii-Key moiety of the invariant chain. Int J Cancer 121 9 (2007) 2031-2041
15. Ambrosino E., Spadaro M., Iezzi M., Curcio C., Forni G., Musiani P., et al. Immunosurveillance of Erbb2 carcinogenesis in transgenic mice is concealed by a dominant regulatory T-cell self-tolerance. Cancer Res 66 15 (2006) 7734-7740
16. Fisk B., Blevins T.L., Wharton J.T., and Ioannides C.G. Identification of an immunodominant peptide of HER-2/neu protooncogene recognized by ovarian tumor-specific cytotoxic T lymphocyte lines. J Exp Med 181 6 (1995) 2109-2117
17. Nakamura Y., Watchmaker P., Urban J., Sheridan B., Giermasz A., Nishimura F., et al. Helper function of memory CD8+ T cells: heterologous CD8+ T cells support the induction of therapeutic cancer immunity. Cancer Res 67 20 (2007) 10012-10018
18. Nishikawa H., Qian F., Tsuji T., Ritter G., Old L.J., Gnjatic S., et al. Influence of CD4+CD25+ regulatory T cells on low/high-avidity CD4+ T cells following peptide vaccination. J Immunol 176 10 (2006) 6340-6346
19. Asemissen A.M., Keilholz U., Tenzer S., Muller M., Walter S., Stevanovic S., et al. Identification of a highly immunogenic HLA-A*01-binding T cell epitope of WT1. Clin Cancer Res 12 24 (2006) 7476-7482
20. Krieg A.M., and Davis H.L. Enhancing vaccines with immune stimulatory CpG DNA. Curr Opin Mol Ther 3 1 (2001) 15-24
21. Davila E., and Celis E. Repeated administration of cytosine-phosphorothiolated guanine-containing oligonucleotides together with peptide/protein immunization results in enhanced CTL responses with anti-tumor activity. J Immunol 165 1 (2000) 539-547
22. Davila E., Velez M.G., Heppelmann C.J., and Celis E. Creating space: an antigen-independent. CpG-induced peripheral expansion of naive and memory T lymphocytes in a full T-cell compartment. Blood 100 7 (2002) 2537-2545
23. Baines J., and Celis E. Immune-mediated tumor regression induced by CpG-containing oligodeoxynucleotides. Clin Cancer Res 9 7 (2003) 2693-2700
24. Krieg A.M. Antitumor applications of stimulating toll-like receptor 9 with CpG oligodeoxynucleotides. Curr Oncol Rep 6 2 (2004) 88-95
25. Rongcun Y., Salazar-Onfray F., Charo J., Malmberg K.J., Evrin K., Maes H., et al. Identification of new HER2/neu-derived peptide epitopes that can elicit specific CTL against autologous and allogeneic carcinomas and melanomas. J Immunol 163 2 (1999) 1037-1044
26. Vertuani S., Sette A., Sidney J., Southwood S., Fikes J., Keogh E., et al. Improved immunogenicity of an immunodominant epitope of the HER-2/neu protooncogene by alterations of MHC contact residues. J Immunol 172 6 (2004) 3501-3508
27. Machlenkin A., Azriel-Rosenfeld R., Volovitz I., Vadai E., Lev A., Paz A., et al. Preventive and therapeutic vaccination with PAP-3, a novel human prostate cancer peptide, inhibits carcinoma development in HLA transgenic mice. Cancer Immunol Immunother 56 2 (2007) 217-226
28. Conforti A., Peruzzi D., Giannetti P., Biondo A., Ciliberto G., La Monica N., et al. A novel mouse model for evaluation and prediction of HLA-A2-restricted CEA cancer vaccine responses. J Immunother 32 7 (2009) 744-754
29. Vertuani S., Triulzi C., Roos A.K., Charo J., Norell H., Lemonnier F., et al. HER-2/neu mediated down-regulation of MHC class I antigen processing prevents CTL-mediated tumor recognition upon DNA vaccination in HLA-A2 transgenic mice. Cancer Immunol Immunother 58 (2009) 653-664
30. Scardino A., Gross D.A., Alves P., Schultze J.L., Graff-Dubois S., Faure O., et al. HER-2/neu and hTERT cryptic epitopes as novel targets for broad spectrum tumor immunotherapy. J Immunol 168 (2002) 5900-5906
31. Kennedy R., and Celis E. Multiple roles for CD4+ T cells in anti-tumor immune responses. Immunol Rev 222 (2008) 129-144
32. Celis E. Toll-like receptor ligands energize peptide vaccines through multiple paths. Cancer Res 67 17 (2007) 7945-7947
33. Rolla S., Nicolo C., Malinarich S., Orsini M., Forni G., Cavallo F., et al. Distinct and non-overlapping T cell receptor repertoires expanded by DNA vaccination in wild-type and HER-2 transgenic BALB/c mice. J Immunol 177 11 (2006) 7626-7633
34. Welters M.J., Kenter G.G., Piersma S.J., Vloon A.P., Lowik M.J., Berends-van der Meer D.M., et al. Induction of tumor-specific CD4+ and CD8+ T-cell immunity in cervical cancer patients by a human papillomavirus type 16 E6 and E7 long peptides vaccine. Clin Cancer Res 14 1 (2008) 178-187
35. Kenter G.G., Welters M.J., Valentijn A.R., Lowik M.J., Berends-van der Meer D.M., Vloon A.P., et al. Phase I immunotherapeutic trial with long peptides spanning the E6 and E7 sequences of high-risk human papillomavirus 16 in end-stage cervical cancer patients shows low toxicity and robust immunogenicity. Clin Cancer Res 14 1 (2008) 169-177
36. Speetjens F.M., Kuppen P.J., Welters M.J., Essahsah F., Voet van den Brink A.M., Lantrua M.G., et al. Induction of p53-specific immunity by a p53 synthetic long peptide vaccine in patients treated for metastatic colorectal cancer. Clin Cancer Res 15 3 (2009) 1086-1095
37. Mittendorf E.A., Peoples G.E., and Singletary S.E. Breast cancer vaccines: promise for the future or pipe dream?. Cancer 110 8 (2007) 1677-1686
38. Mittendorf E.A., Storrer C.E., Foley R.J., Harris K., Jama Y., Shriver C.D., et al. Evaluation of the HER2/neu-derived peptide GP2 for use in a peptide-based breast cancer vaccine trial. Cancer 106 11 (2006) 2309-2317